Medivir: Epiphany Biosciences Plans On Filing An IND For Valomaciclovir (MIV-606) Targeting MS
Main Category: Multiple SclerosisArticle Date: 29 Mar 2009 - 2:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
3.8 (5 votes) |
| Healthcare Prof: |  |
Epiphany Biosciences plans on filing an IND at the FDA to study the potential impact of valomaciclovir in patients with multiple sclerosis. Valomaciclovir, (EBP-348, MIV-606) is a compound licensed from Medivir (STO:MVIRB). One of the multiple contributing factors to the disease MS can be Epstein-Barr virus (EBV) and valomaciclovir is active against EBV and other herpes viruses. MS affects approximately 2.5 million people world-wide and there is no effective treatment. Valomaciclovir is presently in phase IIb clinical trials against zoster (shingles) and phase IIa against mononucleosis (EBV infection).
For more information on Medivir, please see the company website: http://www.medivir.se
Source
Medivir
Visit our multiple sclerosis section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/144050.php>
APA
http://www.medicalnewstoday.com/releases/144050.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
